Table 5.
Summary of the methods used to integrate medication compliance.
| References | Expression | Roles in the model | Source of the data | Statistical methods | ||||
|---|---|---|---|---|---|---|---|---|
| Compliance | Persistence | Retrospective study | Clinical trials | Observational study | Review | |||
| Einarson et al. (15) | √ | √ | (a) Act as branches behind chance nodes, (b) influence the probabilities for events | √ | √ | √ | Simple average | |
| Lachaine et al. (16) | × | × | NA | |||||
| Park et al. (17) | × | √ | Lead to therapy changes | √ | Kaplan-Meier discontinuation curves | |||
| Dilla et al. (18) | × | √ | Lead to therapy changes | √ | ||||
| Anh et al. (19) | √ | × | Not specified | √ | Simple average | |||
| Lubinga et al. (20) | × | √ | Lead to relapse | √ | NA | |||
| Druais et al. (21) | × | √ | (a) Act as transition probabilities, (b) influence relapse of the disease | √ | NA | |||
| Lin et al. (21) | × | √ | Lead to change or discontinuation of the therapy | √ | NA | |||
| Rajagopalan et al. (23) | × | √ | Act as transition probabilities | √ | √ | Regression analysis, partial assumption | ||
| Einarson et al. (24) | √ | √ | (a) Act as branches behind chance nodes, (b) influence the probabilities of events | √ | √ | √ | Partial assumption, simple average | |
| Einarson et al. (25) | √ | √ | (a) Act as branches behind chance nodes, (b) influence the probabilities of events | √ | √ | √ | Partial assumption, simple average | |
| Barnes et al. (26) | Not specified | NA | ||||||
| Einarson et al. (27) | × | √ | (a) Act as branches behind chance nodes, (b) influence the probabilities of events | √ | NA | |||
| Einarson et al. (28) | × | √ | (a) Lead to change or discontinuation of the therapy, (b) influence the relapse of the disease | √ | √ | NA | ||
| Wiwat et al. (29) | √ | √ | Influence relapse of the disease | √ | NA | |||
| Nuhoho et al. (30) | √ | √ | (a) Act as branches behind chance nodes, (b) influence the probabilities of events | √ | NA | |||
| Aigbogun et al. (31) | × | √ | Lead to change or discontinuation of the therapy | √ | Indirect comparison based on data from clinical trials | |||
| Németh et al. (32) | × | × | NA | |||||
| Zhao et al. (33) | √ | √ | Classified different types of patients | √ | √ | √ | Assumption | |
| Abdall-Razak et al. (34) | × | × | NA | |||||
| Dutina et al. (35) | Not specified | NA | ||||||
| Arteaga et al. (36) | × | √ | Act as transition probabilities | √ | √ | NA | ||
| Yi et al. (37) | × | √ | Act as transition probabilities | NA | ||||
| Lin et al. (38) | √ | √ | Classified different types of patients | √ | √ | √ | NA | |
| Jin et al. (39) | √ | √ | Persistence rate acting as transition probabilities while non-compliance seen as reason for non-persistence | √ | √ | NA | ||
NA, not applicable.